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Introduction
Accumulation of amyloid β (Aβ) peptides in senile plaques 
in the cerebral cortex is an early event in the pathogenesis 
of Alzheimer disease (AD) [1]. The longest isoform of Aβ, 
consisting of 42 amino acids (Aβ1-42), is produced from 
amyloid precursor protein (APP) by sequen  tial cleavage by 
β- and γ-secretase in the amyloido  genic APP-processing 
pathway  (Figure  1A)  [2].  β-Secretase  activity  originates 
from an integral membrane aspartyl protease encoded by 
the  β-site  APP-cleaving  enzyme  1  gene  (BACE1)  [3-6] 
whereas  γ-secretase  is  an  intramembrane-cleaving 
complex composed of at least four essential subunits with 
the presenilin (PS1 or PS2) proteins at its enzymatic core 
[7-9].  γ-Secretase,  which  is  one  of  the  top  targets  for 
developing  AD  therapeutics  with  disease-modifying 
effects,  cleaves  the  transmembrane  region  of  APP  to 
produce Aβ of variable length [10-12], with Aβ1-40 being 
the  most  abundant  isoform,  whereas  Aβ1-42  is  most 
prone to aggregation [13-14].
The main focus of using disease-modifying drugs is to 
inhibit  brain  Aβ  production  and  aggregation  and  to 
increase  Aβ  clearance  from  the  brain.  Several  drug 
candidates, including β-secretase and γ-secretase inhibi-
tors  or  Aβ  immunotherapy,  are  being  evaluated  in 
different  phases  in  clinical  trials.  However,  in  a  slowly 
progressive disorder like AD, evaluation of the clinical 
effect of a disease-modifying drug by using rating scales 
requires large patient numbers and extended treatment 
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early effect on symptoms, but instead may show a less-
pronounced  decline  in  cognitive  function  over  years. 
Thus, a great need exists for biomarkers to identify and 
monitor  the  biochemical  effect  of  disease-modifying 
drugs in AD clinical trials. Such biomarker data providing 
evidence directly in patients with AD that the drug has 
the predicted mechanism of action may be valuable for 
making  a  go/no-go  decision  for  large  and  expensive 
Phase II or III clinical trials.
In animal studies, a decrease in soluble Aβ levels and 
Aβ  accumulation  has  been  reported  in  response  to  γ-
secretase inhibition [15-18]. Recently, in a human clinical 
trial,  it  was  shown,  by  using  enzyme-linked  immuno-
sorbent  assay  (ELISA),  that  the  γ-secretase  inhibitor 
LY450139  reduces  the  concentration  of  Aβ1-40  and 
Aβ1-42 in human plasma in a dose-dependent manner, 
where  as  a  significant  decrease  in  human  cerebrospinal 
fluid (CSF) Aβ levels was not detected [19]. However, by 
using  a  stable  isotope-labeling  kinetic  (SILK)  method, 
which can be used to measure central nervous system 
(CNS) production and clearance rates of total Aβ in the 
CSF  of  humans  [20],  it  was  shown  that  LY450139 
significantly decreased Aβ production without affecting 
Aβ clearance in the CNS [21].
We recently identified a set of 18 N- and C-terminally 
truncated Aβ peptides in human CSF by using immuno-
precipitation-mass  spectrometry  (IP-MS)  and  showed 
that CSF Aβ1-16 may be a novel positive biomarker for 
AD  that  was  elevated  in  AD  patients  [22].  This  novel 
biomarker  for  AD  is  generated  through  a  previously 
unrecognized metabolic pathway by concerted β- and α-
secretase cleavage of APP (Figure 1B) [23]. Further, the 
relative level of Aβ1-16, along with Aβ1-14 and Aβ1-15, 
has previously been shown to be elevated in cell media 
and in CSF from mice in response to γ-secretase inhibitor 
Figure 1. Schematic drawing of APP and generation of Aβ isoforms. The 17-amino acid signal peptide is indicated at the N-terminus. A single 
membrane-spanning domain is located at amino acids 700-723 in the longest APP isoform (APP770). (a) In the amyloidogenic pathway, β-secretase 
cleaves after residue 671, generating β-sAPP, which is secreted, and a C-terminal fragment (β-CTF or C99), which is retained in the membrane. The 
β-CTF fragment can undergo further cleavage by γ-secretase to release Aβ isoforms. (b) In another pathway, APP is first cleaved by β-secretase, 
but after this, by α-secretase, thus generating the shorter isoforms Aβ1-14, Aβ1-15, and Aβ-16. In another described nonamyloidogenic pathway, 
α-secretase cleaves between amino acids 16 and 17 in the Aβ sequence generating α-sAPP, followed by γ-secretase cleavages, generating a 
fragment called p3 (Aβ17-40/42). This 3-kDa fragment has been isolated from cell-culture medium [29] and in brains from AD patients [30]. 
However, the fragment has never been detected in human CSF. AICD, APP intracellular domain; APP, amyloid precursor protein; Aβ, amyloid β; sAPP, 
soluble amyloid precursor protein.
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Page 2 of 7treatment  [23,24],  suggesting  that  these  shorter  Aβ 
isoforms  may  be  sensitive  biomarkers  for  γ-secretase 
inhibitor treatment. Here, we tested the hypothesis that 
treatment of AD patients with the γ-secretase inhibitor 
LY450139 can be monitored by increased CSF levels of 
Aβ1-14, Aβ1-15, and Aβ1-16.
Materials and methods
Study participants and sample collection
The  study  cohort  and  clinical  procedures  have  been 
described before in detail [19]. In brief, 51 patients were 
enrolled  at  six  academic  research  centers  between 
October 1, 2005, and December 31, 2006 (Figure 2a). The 
protocol was reviewed and approved by the institutional 
review  board  at  each  participating  site.  All  research 
participants  and  caregivers  gave  written  informed 
consent. Of the 51 patients enrolled in the study, CSF 
samples from 35 patients were available for analysis by 
IP-MS. See Table 1 for demographic data.
Participants were 50 years or older and diagnosed as 
having probable AD, as defined by the National Institute 
of  Neurological  and  Communicative  Disorders  and 
Stroke and the Alzheimer Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria [25]. Individuals 
receiving  stable  doses  of  cholinesterase-inhibitor  drugs 
or memantine were included. The trial was a multicenter, 
randomized,  double-blind,  placebo-controlled,  dose-
escalation study (Figure 2a). Participants were random  ized 
to receive LY450139 or placebo by using a 2:1 randomi-
zation  scheme  through  a  telephone-based  inter  active 
voice-response system (Figure 2b). Patients ran  dom  ized to 
the LY450139 groups received 60 mg/d for 2 weeks, and 
then  100  mg/d  for  the  next  6  weeks.  At  8  weeks,  the 
treatment arm was randomized again to receive 6 addi-
tional weeks of treatment at 100 or 140 mg/d.
The  CSF  samples  were  collected  into  polypropylene 
tubes  by  means  of  a  lumbar  puncture  at  baseline  and 
approximately 6 hours after the administration of the last 
dose of LY450139 at week 14.
APP measurements
CSF concentrations of α-secretase-cleaved soluble APP 
(α-sAPP) and β-secretase-cleaved soluble APP (β-sAPP) 
were  determined  by  using  the  MSD  sAPPα/sAPPβ 
multiplex assay, as described by the manufacturer (Meso 
Scale  Discovery,  Gaithersburg,  MD,  USA).  This  assay 
uses  the  6E10  antibody  to  capture  α-sAPP  and  a 
neoepitope-specific  antibody  to  capture  β-sAPP.  Both 
isoforms are detected by the SULFO-TAG-labeled anti-
APP antibody p2-1.
IP-MS
IP was combined with matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) MS for analyzing 
the Aβ isoform pattern in a single analysis. The IP-MS 
was conducted as described before [26]. In brief, 8 mg of 
the monoclonal antibody 6E10 (Aβ epitope 4–9; Signet 
Laboratories,  Inc.,  Dedham,  MA,  USA)  was  added  to 
50 ml Dynabeads M-280 (Dynal) sheep anti-mouse and 
left overnight on a rocking platform (+4°C). The IP was 
conducted  overnight  (+4°C)  on  940  ml  CSF,  to  which 
10  ml  2.5%  Tween-20  (Bio-Rad  Laboratories,  Inc.)  had 
been added. The beads/CSF solution (total volume, 1 ml) 
was transferred to a KingFisher magnetic particle proces-
sor (polypropylene tubes; Thermo Scientific) for washing 
and  elution  in  a  five-step  procedure.  The  collected 
Figure 2. Data flowchart for the trial. (a) The intention-to-treat 
analyses included all 51 patients originally randomized, including all 
subsequent dropouts. Of the 51 patients, 35 were analyzed by using 
IP-MS. (b) Study design.
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redissolved in 5 ml 0.1% formic acid in 20% acetonitrile.
The  samples  were  analyzed  with  MALDI-TOFMS 
(Autoflex, Bruker Daltonics, Bremen, Germany) operat-
ing in reflector mode. The acquired MS data were anal-
yzed  by  the  software  Medicwave  Bioinformatics  Suite 
(MBS)  by  using  the  immunoprecipitation  for  MALDI 
(IPM)  module  (MedicWave,  Halmstad,  Sweden)  for 
automatic  processing  of  the  all  spectra.  In  brief,  after 
internal calibration, baseline subtraction, and smoothing, 
the  peaks  for  each  spectrum  were  integrated  with  the 
integration  limits  −2  to  +5  m/z  relative  to  the  mono-
isotopic  peak.  Before  the  statistical  analysis,  the  peak 
areas were normalized to the sum of the integrated peaks, 
duplicated  samples  were  averaged,  and  the  relative 
changes compared with baseline values were calculated, 
as described previously [22].
Group differences were analyzed by using the Kruskal-
Wallis test, and in case of significance (P < 0.05), followed 
by Mann-Whitney test to identify the differences.
Results
Representative CSF Aβ isoform mass spectra from an AD 
patient before treatment and after 14 weeks on the high 
dosage of the γ-secretase inhibitor LY450139 are shown 
in Figure 3a. The treatment greatly increased the mass 
spectrometric  signal  for  Aβ1-14,  Aβ1-15,  and  Aβ1-16, 
whereas the mass spectrometric signal corresponding to 
Aβ1-34 decreased as a response to treatment (Kruskal-
Wallis test, P = 0.009, 0.01, 0.05, and 0.000041, respec-
tively). The other Aβ isoforms reproducibly detected in 
all  spectra  (Aβ1-17,  Aβ1-18,  Aβ1-19,  Aβ1-33,  Aβ1-37, 
Aβ1-38, Aβ1-40, and Aβ1-42) did not differ significantly 
in intensity before and after treatment. The levels of the 
Aβ  isoforms  Aβ1-13  and  Aβ1-20  were  low,  were  not 
detected in all samples, and were therefore omitted from 
further analysis. The mass-to-charge (m/z) ratio of Aβ1-
18 [M + H]+ is almost identical to the m/z of the second 
charge state of Aβ1-40 [M + 2H]2+ and therefore difficult 
to quantify; it was excluded from further analysis.
In the 100-mg group, after drug administration at week 
14, the CSF levels of Aβ1-14, Aβ1-15, and Aβ1-16 were 
significantly increased by a mean of 57%, 21%, and 30%, 
respectively,  whereas  Aβ1-34  decreased  39%  (see 
Figure 3b and Table 2) compared with study baseline. The 
same  result  was  seen  in  the  140-mg  group,  Aβ1-14, 
Aβ1-15  and  Aβ1-16  were  increased  by  means  of  74%, 
35%,  and  67%,  respectively,  whereas  Aβ1-34  decreased 
37% (Table 2). No statistically significant changes were 
seen for any other Aβ isoforms detected. α-sAPP showed 
a tendency to increased levels (13%) in the 140-mg group, 
whereas  β-sAPP  was  unaffected  by  all  the  treatments 
(Figure 3c).
Discussion
Intense multidisciplinary research efforts during the last 
decades  have  provided  detailed  knowledge  on  the 
molecular pathogenesis of AD, which has been translated 
into  novel  promising  therapies  with  putative  disease-
modifying  effects.  Several  promising  drug  candidates, 
such as Aβ immunotherapy and secretase inhibitors, are 
now being tested in clinical trials. However, because the 
predicted clinical effect of this type of disease-modifying 
drugs is a less-pronounced slope in the rate of cognitive 
deterioration, without any early symptomatologic effect, 
very large clinical trials with extended treatment periods 
will be needed to identify a beneficial clinical effect by 
using  rating  scales.  Thus,  biomarker  evidence  from 
smaller  short-term  clinical  trials  that  the  drug  has  the 
predicted biochemical mode of action directly in patients 
with  AD  would  be  valuable  for  making  a  go/no-go 
Table 1. Participant characteristics at baseline
Characteristic  Placebo (n = 10)  LY450139, 100 mg (n = 15)  LY450139, 140 mg (n = 10)
Demographics
  Age, mean (SD, years)  69.1 (8.81)  72.4 (8.13)  68.8 (9.02)
  Female sex, number (%)  5 (50)  10 (66.6)  4 (40)
  APOE e4 carriers, number (%)  8 of 10 (80)  11 of 13 (84.6)  7 of 9 (77.8)
Clinical scores, mean (SD)
  MMSE  18.3 (4.0)  22 (3.6)  24.9 (1.4)
  ADCS-ADL  61.9 (7.3)  67.7 (8.4)  70.6 (7.8)
  ADAS-Cog 11  26.9 (10.0)  19.9 (6.3)  17.9 (5.8)
ADAS-Cog 11, Alzheimer’s Disease Assessment Scale Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale; APOE, 
apolipoprotein E; MMSE, Mini-Mental State Examination.
Table 2. Summary of Mann-Whitney test for peptides
  Placebo vs. 100 mg  Placebo vs. 140 mg  100 mg vs. 140 mg
Aβ1-14  0.002  0.03  0.58
Aβ1-15  0.04  0.004  0.17
Aβ1-16  0.05  0.003  0.04
Aβ1-34  0.00005  0.0002  0.82
Kruskal-Wallace test, P < 0.05.
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great need exists for biomarkers to identify and monitor 
the biochemical effect of disease-modifying drugs in AD 
clinical trials.
The  main  focus  with  disease-modifying  drugs  is  to 
inhibit  brain  Aβ  production  and  aggregation  and  to 
increase Aβ clearance from the brain. γ-Secretase inhibi-
tors have previously been shown to reduce Aβ1-40 and 
Aβ1-42 production and secretion in cells and to reduce 
soluble  Aβ  and  amyloid  plaque  burden  in  mice 
[10,15-18,23].  These  results  have  made  the  γ-secretase 
complex  one  of  the  top  targets  for  developing  AD 
therapeutics. Here we show that the novel Aβ isoforms 
Aβ1-14, Aβ1-15, and Aβ1-16, together with Aβ1-34, may 
serve as sensitive biomarkers for γ-secretase inhibition by 
LY450139 in the CNS of AD patients.
In a previous study using ELISA measurements of CSF 
Aβ1-40  and  Aβ1-42,  the  expected  reduction  of  the 
peptides  in  response  to  LY450139  treatment  was  not 
found  [19].  It  was  suggested  that  this  lack  of  changes 
might be the result of a rapid transport of Aβ from CSF 
into  plasma  or  that  longer  treatment  duration  may  be 
required to identify changes [19]. In another study using 
the SILK method to examine whether an effect on Aβ 
production could be identified with LY450139 treatment, 
it was shown that Aβ production in the CNS decreased 
while  Aβ  clearance  remained  stable  [21].  The  lack  of 
effect on CSF Aβ1-40 and Aβ1-42, despite the reduced 
Aβ production, may be because the different techniques 
are  measuring  different  targets.  SILK  analysis  of  Aβ 
turnover requires that all Aβ isoforms are digested with 
trypsin before analysis, and a cleavage product consisting 
of  Aβ17-28  is  then  measured  by  using  MS  [20].  Thus, 
total Aβ (that is, the mean of all of the very different Aβ 
isoforms that contain the Aβ17-28 sequence) is measured. 
This  means  that  all  longer  isoforms  detected  in  the 
present study (Aβ1-33, Aβ1-34, Aβ1-37, Aβ1-38, Aβ1-40, 
and Aβ1-42) will contribute to the mass spectrometric 
signal. The results presented herein suggest that the reduc-
tion  in  Aβ1-34,  the  generation  of  which  is  γ-secretase 
dependent  [10-11,27],  may  contribute  to  the  overall 
reduction  of  Aβ  detected  in  CSF  by  using  the  SILK 
method.
Previous experimental studies on certain cultured cells 
expressing  wild-type  human  APP  have  shown  that  γ-
secretase  inhibitor  can  increase  in  α-  and  β-secretase 
cleavage  products  along  with  the  expected  increase  in 
APP C-terminal fragments (C99 APP-CTF) [28]. Further, 
recent data have shown that the levels of Aβ1-14, Aβ1-15, 
and  Aβ1-16  are  elevated  in  cell  media  and  CSF  from 
transgenic mice treated with γ-secretase inhibitors and 
that these shorter isoforms are derived from concerted 
cleavages of APP by β- and α-secretase, thus reflecting a 
third  metabolic  pathway  for  APP  [23,24].  Data  in  this 
study  suggest  that  these  shorter  Aβ  isoforms  may  be 
sensitive  novel  biomarkers  for  γ-secretase  inhibitor 
treatment, even at doses that do no affect the CSF levels 
of Aβ1-40 or Aβ1-42. The increased levels of the isoforms 
detected after γ-secretase inhibitor treatment might be 
explained by an increased amount of substrate (that is, 
Figure 3. Representative mass spectra. (a) Representative mass 
spectra from an AD patient displaying the Aβ-isoform pattern before 
treatment (red spectra) and after treatment with 140 mg of the 
γ-secretase inhibitor LY450139 (blue spectra). The mass spectrometric 
signal of Aβ1-14/15/16 increased, whereas Aβ1-34 decreased. 
The longer isoforms, including Aβ1-17, Aβ1-40, and Aβ1-42, were 
unaffected by the treatment. The relative change as a response to 
treatment is displayed for (b) all Aβ isoforms detected in all samples 
and (c) α-sAPP and β-sAPP. The error bars represent standard errors 
of the mean.
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cleaved by β-secretase.
Here  we  verify  these  findings  directly  in  living  AD 
patients (that is, a major increase of the shorter isoforms 
and a slight increase of α-sAPP, in CSF from AD patients 
treated with a γ-secretase inhibitor). The unchanged CSF 
levels  of  Aβ1-40  and  Aβ1-42  are  in  agreement  with 
previous studies [19] and suggest that these markers are 
less sensitive to detect γ-secretase inhibition as compared 
with Aβ1-14, Aβ1-15, and Aβ1-16, possibly because they 
may be influenced by other factors, such as brain amyloid 
load and/or Aβ oligomerization or that they are present 
at higher levels in CSF and that higher doses are needed 
to  detect  effects  on  these  biomarkers  in  AD  patients. 
Unchanged β-sAPP levels and only slightly elevated α-
sAPP levels suggest that γ-secretase inhibition does not 
result in any major change in the release of these APP 
fragments to the CSF. It is at this stage unclear whether 
these fragments are degraded further or if they simply are 
present  in  such  high  concentrations  in  the  CSF  that  a 
very high γ-secretase inhibitor dose is needed to detect 
an effect on CSF α-sAPP and β-sAPP levels.
Conclusions
This study suggests that Aβ1-14, Aβ1-15, and Aβ1-16 are 
positive  and  very  sensitive  biomarkers  for  γ-secretase 
inhibition and can be used to detect biochemical effects on 
APP  processing  in  AD  patients  treated  with  LY450139. 
Long-term clinical trials are needed to reveal whether these 
biomarkers predict a beneficial clinical treatment effect.
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